Bessemer Group Inc. Has $1.61 Million Position in Repligen Corporation $RGEN

Bessemer Group Inc. lessened its position in shares of Repligen Corporation (NASDAQ:RGEN) by 95.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,079 shares of the biotechnology company’s stock after selling 238,450 shares during the period. Bessemer Group Inc.’s holdings in Repligen were worth $1,614,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in RGEN. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Repligen by 3,219.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after purchasing an additional 400,970 shares in the last quarter. Geneva Capital Management LLC raised its holdings in shares of Repligen by 239.6% during the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after buying an additional 343,991 shares in the last quarter. Blue Whale Capital LLP bought a new stake in shares of Repligen during the 2nd quarter worth $35,782,000. Norges Bank acquired a new stake in Repligen in the second quarter valued at about $30,991,000. Finally, Schroder Investment Management Group bought a new position in Repligen in the second quarter valued at about $25,672,000. 97.64% of the stock is owned by institutional investors.

Insider Transactions at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares in the company, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 49,657 shares of company stock worth $7,721,077 over the last three months. 1.20% of the stock is owned by company insiders.

Repligen Stock Performance

Shares of RGEN stock opened at $142.18 on Monday. The stock has a market capitalization of $8.00 billion, a PE ratio of 7,112.56, a PEG ratio of 2.59 and a beta of 1.13. The business’s 50 day simple moving average is $161.90 and its 200 day simple moving average is $145.25. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. Repligen Corporation has a one year low of $102.96 and a one year high of $175.77.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on RGEN shares. Canaccord Genuity Group increased their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. UBS Group increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, January 30th. Finally, Barclays boosted their price objective on Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $179.62.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.